Li Tao, PhD, discusses early US uptake of twice-yearly lenacapavir, faster prescription-to-injection timelines, and how ACA coverage milestones tracked with zero cost sharing and HIV diagnoses.
|Videos|March 5, 2020
Barriers to PrEP Implementation
Author(s)Contagion® Editorial Staff
Colleen Kelley, MD, MPH, describes barriers to the implementation of HIV pre-exposure prophylaxis.
Advertisement
Segment Description: Colleen Kelley, MD, MPH, associate professor at the Emory University School of Medicine, describes barriers to the implementation of HIV pre-exposure prophylaxis.
Interview Transcript (modified slightly for readability):
Kelley: I do think we are seeing declines [in HIV incidence] in areas that have done a great job implementing pre-exposure prophylaxis. The issue is implementation. It's getting pre-exposure prophylaxis to the people who need it the most, and supporting them to be able to use it during times when they may be at risk for HIV. Implementation and access are big barriers. After that is successfully supporting people to persist on PrEP, to continue taking it through the period of time where they might be at risk for HIV. Currently I think those are the 3 biggest barriers: implementation, access, and persistence on pre-exposure prophylaxis.
Advertisement
Related to this article
Dr. Reddy’s generic twice-yearly lenacapavir received FDA tentative approval for HIV PrEP. It is expected to cost $40 a year in 120 low- and middle-income countries (LMICs), with first supplies due by the end of 2026.
Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
Advertisement
Advertisement
Trending on Contagion Live
1
Ebola Update: DRC Outbreak Tops 10,000 Cases as Kenya, Nigeria Report Spread
2
Is the mRNA Influenza Vaccine More Efficacious in Older Adults?
3
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
4
CDC Updates Report on Antimicrobial Resistance
5